BCBA/GSK (BCBA/GSK)

Buenos Aires Stock Exchange: BCBA/GSK · ARS

ARS 20,140

-890.00 (-4.2%)· Recorded snapshot

Market cap	150.3T
Revenue (ttm)	67.9T
Net income (ttm)	8.8T
EPS (ttm)	ARS 1,173
P/E (trailing)	17.2x
P/E (forward)	9.7x
Dividend	ARS 573 (2.85%)
Volume	6,586

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 67.9T
Net income (ttm): 8.8T
EPS (ttm): ARS 1,173
P/E (trailing): 17.2x
P/E (forward): 9.7x
Market cap: 150.3T

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 13:30 UTC

Forward P/E9.7

P25 n/aP50 n/aP75 n/a

Trailing P/E17.2

P25 n/aP50 n/aP75 n/a

ROE28.3

P25 n/aP50 n/aP75 n/a

ROIC24.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BCBA/GSK indicators

Market & fundamental data

Available fields

247

Groups with data

Currency

GBP

Showing 247 of 247 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	ARS
Country	United Kingdom
Country code	AR
Earnings date	2026-10-28
Employees	66,841
Employees change	-1,583
Employees growth	-2.25%
Enterprise value	ARS 192.1T
Exchange	Buenos Aires Stock Exchange
Financial currency	GBP
Financial report date	2026-09-30
First seen	2026-05-10
Fiscal year end	December
Founded	1715
Industry	Drug Manufacturers - General
Is primary listing	No
ISIN number	ARDEUT110483
Last earnings date	2026-10-28
Last refreshed	2026-10-29
Last stock split date	2022-07-22
Last stock split type	Reverse
Market cap	ARS 150.3T
Next earnings date	2027-02-03
Price	ARS 20,140.00
Price currency	ARS
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	bcba/GSK
Website	https://www.gsk.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	21.56x
Average P/E ratio (3Y)	16.33x
Average P/E ratio (5Y)	13.77x
Earnings yield	5.82%
EV/Earnings	21.81x
EV/EBIT	9.56x
EV/EBITDA	7.38x
EV/FCF	12.79x
EV/Sales	2.8x
FCF / EV yield	7.82%
FCF yield	10%
Forward P/E	9.73x
Graham number	11504.65615
Graham upside	-42.88%
Lynch fair value	ARS 5,903.19
Lynch upside	-70.69%
P/(FCF - SBC) ratio	10.53x
P/(OCF - SBC) ratio	8.69x
P/B ratio	4.04x
P/E ratio	17.17x
P/FCF ratio	10x
P/OCF ratio	8.32x
P/S ratio	2.21x
Price/EBITDA ratio	6.7x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	29.31%
EBITDA margin	33.02%
Effective tax rate	10.42%
FCF margin	21.83%
Gross margin	73.79%
Operating margin	29.31%
Pretax margin	16.05%
Profit margin	12.97%
Profit per employee	ARS 131.8M
Profitable quarters	8
Profitable years	41
Revenue per employee	ARS 1B
ROA	9.24%
ROA (5Y)	7.23%
ROCE	19.28%
ROE	28.27%
ROE (5Y)	32.1%
ROIC	24.61%
ROIC (5Y)	22.54%
SBC / revenue	1.11%
Tax / revenue	1.67%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-19.72%
EPS growth (Q)	-22.81%
EPS growth (QoQ)	254.21%
EPS growth 10Y	30.09%
EPS growth 3Y	-10.33%
EPS growth 5Y	0%
EPS growth years	1
FCF growth	14.66%
FCF growth (Q)	27.42%
FCF growth (QoQ)	3.09%
FCF growth 3Y	20.79%
FCF growth 5Y	1.32%
Gross profit growth	6.23%
Gross profit growth (Q)	5.53%
Gross profit growth 3Y	5.77%
Gross profit growth 5Y	6.43%
Net income growth	-20.81%
Net income growth (Q)	-23.35%
Net income growth (QoQ)	254.71%
Net income growth 3Y	-10.52%
Net income growth 5Y	0.18%
Net income growth years	1
OCF growth	14.45%
OCF growth (Q)	26.42%
OCF growth (QoQ)	4.42%
OCF growth 10Y	5.94%
OCF growth 3Y	17.65%
OCF growth 5Y	2.09%
Operating income growth	11.46%
Operating income growth (Q)	-7.33%
Operating income growth 3Y	8.97%
Operating income growth 5Y	8.44%
Revenue growth	4.28%
Revenue growth (Q)	3.98%
Revenue growth (QoQ)	5.68%
Revenue growth 10Y	2.35%
Revenue growth 3Y	4.2%
Revenue growth 5Y	4.94%
Revenue growth quarters	8
Revenue growth years	4

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	ARS -3T
Depreciation and amortization	ARS 2.6T
EBIT	ARS 19.9T
EBITDA	ARS 22.4T
EPS	ARS 1,173.01
Financing cash flow	ARS 3.9T
Free cash flow	ARS 15T
Free cash flow minus SBC	ARS 14.3T
Gross profit	ARS 50.1T
Income taxes	ARS 1.1T
Investing cash flow	ARS -22.1T
Net borrowing	ARS 12.9T
Net cash flow	ARS -157.9B
Net income	ARS 8.8T
Operating cash flow minus SBC	ARS 17.3T
Operating income	ARS 19.9T
Revenue	ARS 67.9T
Stock-based compensation	ARS 757.2B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.98
Book value per share	ARS 9,470.47
Debt / EBITDA	2.11
Debt / equity	1.3
Debt / FCF	3.21
Goodwill	ARS 16.9T
Interest coverage	14.94
Long-term assets	ARS 108.4T
Long-term liabilities	ARS 65.5T
Net cash (debt)	ARS -42.2T
Net cash / market cap	-28.08%
Net debt / EBITDA	1.88
Net debt / equity	1.13
Net debt / FCF	2.81
Piotroski F-Score	6
Property, plant and equipment	ARS 20.8T
Shareholders' equity	ARS 37.2T
Tangible book value	ARS -29.6T
Tangible book value per share	ARS -7,389.94
Total assets	ARS 145.2T
Total cash	ARS 6T
Total debt	ARS 48.2T
Total liabilities	ARS 108T

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.5
Current assets	ARS 36.7T
Current liabilities	ARS 42.5T
Current ratio	0.86
Inventory turnover	1.42
Net working capital	ARS -7.7T
Quick ratio	0.55
Working capital	ARS -5.7T
Working capital turnover	-21,499.82

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.37%
Dividend growth	38.94%
Dividend growth (10Y)	48.71%
Dividend growth (3Y)	95.42%
Dividend growth (5Y)	121.16%
Dividend growth years	4
Dividend payment date	2026-10-08
Dividend payment years	5
Dividend payout frequency	Quarterly
Dividend per share	ARS 573.36
Dividend yield	2.85%
Ex-dividend date	2026-08-14
Last dividend	ARS 149.12
Payout ratio	62.01%
Shareholder yield	4.21%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	ARS 19,964.13
1D price change	-4.23%
1M price change	1.1%
1M total return	1.1%
1W price change	-1.42%
1W total return	-1.42%
1Y price change	23.62%
1Y return CAGR	27.45%
1Y total return	27.43%
20-day SMA	ARS 19,752.00
200-day SMA	ARS 20,013.15
3M price change	-2.75%
3M total return	-1.92%
3Y price change	169.49%
3Y return CAGR	43.37%
3Y total return	194.76%
50-day SMA	ARS 19,961.20
50-day SMA vs 200-day SMA	50under200
52-week high	ARS 22,760.00
52-week high date	2026-02-18
52-week low	ARS 15,980.00
52-week low date	2025-10-28
5Y price change	691.94%
5Y return CAGR	54.84%
5Y total return	789.9%
6M price change	-1.66%
6M total return	-0.07%
All-time high	ARS 22,760.00
All-time high date	2026-02-18
All-time low	ARS 543.13
All-time low date	2019-07-05
Average true range (ATR)	ARS 475.89
Average volume	1.3K
Change from 52-week high	-11.51%
Change from 52-week low	26.03%
Change from all-time high	-11.47%
Change from all-time low	3,610.01%
Change from open	1.46%
Day's gap	-5.61%
Dollar volume	ARS 132.6M
High price	ARS 20,470.00
Low price	ARS 19,850.00
Monthly RSI	66.47
Open price	ARS 19,850.00
Position in 52-week range	46.77%
Previous close	ARS 21,030.00
Price vs 150-day SMA	0.93%
Price vs 20-day SMA	2.01%
Price vs 200-day SMA	0.68%
Price vs 50-day SMA	0.95%
Relative volume	5.12
RSI	50.88
Sharpe ratio	0.7
Sharpe ratio (3Y)	1.08
Sharpe ratio (5Y)	1.28
Sortino ratio	1.27
Sortino ratio (3Y)	1.86
Sortino ratio (5Y)	2.11
Volume	6.6K
Weekly RSI	51.82
YTD price change	7.81%
YTD total return	10.3%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3.9B
Shares change (QoQ)	0.27%
Shares change (YoY)	-1.37%
Shares held by insiders	0.06%
Shares held by institutions	84.53%

Deeper analysis on BCBA/GSK

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BCBA/GSK report

Is a complete BCBA/GSK research report available?

No complete published report is available for bcba/GSK (BCBA/GSK) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BCBA/GSK (BCBA/GSK)

Price

Financial snapshot

Fair-value bridge

Latest news · BCBA/GSK

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BCBA/GSK indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BCBA/GSK

Frequently asked questions